Research Progress on lncRNA Functions and Mechanisms in Pituitary Adenomas

2020 ◽  
Vol 52 (05) ◽  
pp. 280-288 ◽  
Author(s):  
Qiu Du ◽  
De-shan Yao ◽  
You-wei Wang ◽  
Cheng Cheng
Keyword(s):  
Early Diagnosis ◽  
Neuroendocrine Tumor ◽  
Tumor Cells ◽  
Pituitary Adenomas ◽  
Prognostic Markers ◽  
Research Progress ◽  
Non Coding Rna ◽  
Long Non Coding Rna

AbstractDespite being the most common human neuroendocrine tumor, the pathogenesis of pituitary adenomas (PAs) is still unclear. Long non-coding RNA (lncRNA) is involved in a variety of physiological and pathological processes, and has been shown to play a key role in the process of tumor instigation and development by affecting the proliferation, migration, invasiveness, and metastasis of tumor cells. Therefore, lncRNAs may be used as diagnostic and prognostic markers of tumors. In this paper, the effect of lncRNA on the onset and progression of PAs is reviewed so as to provide a profound understanding of its pathogenesis and clinical reference for the early diagnosis of PAs.

scholarly journals Down-regulated LncR-MALAT1 suppressed cell proliferation and migration by inactivating autophagy in bladder cancer

RSC Advances ◽  
2018 ◽  
Vol 8 (54) ◽  
pp. 31019-31027
Author(s):  
Jiude Qi ◽  
Yanfeng Chu ◽  
Guangyan Zhang ◽  
Hongjun Li ◽  
Dongdong Yang ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Bladder Cancer ◽  
Lung Adenocarcinoma ◽  
Tumor Cells ◽  
Cell Proliferation And Migration ◽  
Non Coding Rna ◽  
And Migration ◽  
Long Non Coding Rna ◽  
Proliferation And Migration

Long non-coding RNA-metastasis-associated lung adenocarcinoma transcript (LncR-MALAT) is highly expressed in a variety of tumors, which can affect the progression of tumor cells.

scholarly journals Role of long non-coding RNA H19 in the development of osteoporosis

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Senxiang Chen ◽  
Da Liu ◽  
Zimo Zhou ◽  
Sen Qin
Keyword(s):  
Molecular Mechanisms ◽  
The Body ◽  
Research Progress ◽  
Effective Prevention ◽  
Treatment Of Osteoporosis ◽  
Non Coding Rna ◽  
Metabolic Bone ◽  
Different Types ◽  
Long Non Coding Rna

Abstract Background Osteoporosis is a widespread and serious metabolic bone disease. At present, revealing the molecular mechanisms of osteoporosis and developing effective prevention and treatment methods are of great significance to health worldwide. LncRNA is a non-coding RNA peptide chain with more than 200 nucleotides. Researchers have identified many lncRNAs implicated in the development of diseases and lncRNA H19 is an example. Results A large amount of evidence supports the fact that long non-coding RNA (lncRNA) genes, such as H19, have multiple, far-reaching effects on various biological functions. It has been found that lncRNA H19 has a role in the regulation of different types of cells in the body including the osteoblasts, osteocytes, and osteoclasts found in bones. Therefore, it can be postulated that lncRNA H19 affects the incidence and development of osteoporosis. Conclusion The prospect of targeting lncRNA H19 in the treatment of osteoporosis is promising because of the effects that lncRNA H19 has on the process of osteogenic differentiation. In this review, we summarize the molecular pathways and mechanisms of lncRNA H19 in the pathogenesis of osteoporosis and summarize the research progress of targeting H19 as a treatment option. Research is emerging that explores more effective treatment possibilities for bone metabolism diseases using molecular targets.

scholarly journals RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies

Diagnostics ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. 60 ◽  
Author(s):  
Marvin Lim ◽  
Anne-Marie Baird ◽  
John Aird ◽  
John Greene ◽  
Dhruv Kapoor ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Biology ◽  
Prognostic Markers ◽  
Circular Rna ◽  
Liquid Biopsies ◽  
Non Coding Rna ◽  
Cancer Initiation ◽  
Long Non Coding Rna ◽  
Active Investigation

The treatment landscape of prostate cancer has evolved rapidly over the past five years. The explosion in treatment advances has been witnessed in parallel with significant progress in the field of molecular biomarkers. The advent of next-generation sequencing has enabled the molecular profiling of the genomic and transcriptomic architecture of prostate and other cancers. Coupled with this, is a renewed interest in the role of non-coding RNA (ncRNA) in prostate cancer biology. ncRNA consists of several different classes including small non-coding RNA (sncRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA). These families are under active investigation, given their essential roles in cancer initiation, development and progression. This review focuses on the evidence for the role of RNAs in prostate cancer, and their use as diagnostic and prognostic markers, and targets for treatment in this disease.

scholarly journals ceRNA Network Analysis Shows That lncRNA CRNDE Promotes Progression of Glioblastoma Through Sponge mir-9-5p

2021 ◽  
Vol 12 ◽  
Author(s):  
Xiaobin Luo ◽  
Tianqi Tu ◽  
Yali Zhong ◽  
Shangyi Xu ◽  
Xiangzhou Chen ◽  
...  
Keyword(s):  
Survival Rate ◽  
Messenger Rna ◽  
Target Genes ◽  
Prognostic Markers ◽  
Cerna Network ◽  
Therapeutic Drugs ◽  
Non Coding Rna ◽  
Field Therapy ◽  
Multiple Treatments ◽  
Long Non Coding Rna

Glioblastoma accounts for 45.2% of central nervous system tumors. Despite the availability of multiple treatments (e.g., surgery, radiotherapy, chemotherapy, biological therapy, immunotherapy, and electric field therapy), glioblastoma has a poor prognosis, with a 5-year survival rate of approximately 5%. The pathogenesis and prognostic markers of this cancer are currently unclear. To this end, this study aimed to explore the pathogenesis of glioblastoma and identify potential prognostic markers. We used data from the GEO and TCGA databases and identified five genes (ITGA5, MMP9, PTPRN, PTX3, and STX1A) that could affect the survival rate of glioblastoma patients and that were differentially expressed between glioblastoma patients and non-tumors groups. Based on a variety of bioinformatics tools for reverse prediction of target genes associated with the prognosis of GBM, a ceRNA network of messenger RNA (STX1A, PTX3, MMP9)-microRNA (miR-9-5p)-long non-coding RNA (CRNDE) was constructed. Finally, we identified five potential therapeutic drugs (bacitracin, hecogenin, clemizole, chrysin, and gibberellic acid) that may be effective treatments for glioblastoma.

Sign in / Sign up

Export Citation Format

Share Document